Micro
Developing
Active
ABBV acquisition of Apogee Therapeutics
Gaining traction — growing article coverage and momentum.
Score
0.5
Velocity
▲ 1.0
Articles
3
Sources
2
Sentiment Timeline
Event Timeline
🤖
AI Overview
What happened: AbbVie Inc (NYSE:ABBV) agreed to acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash deal valued at approximately $10.9 billion. This acquisition, AbbVie's largest since 2019, adds a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma, to AbbVie's portfolio.
Market impact: The healthcare sector, particularly biopharmaceutical companies, is affected. AbbVie, a major player, is diversifying its pipeline, potentially driving future growth. Apogee shareholders benefit from a 60% premium, while AbbVie investors may scrutinize the deal's impact on AbbVie's valuation, which currently trades at a richer multiple than Nvidia.
What to watch next: AbbVie's shareholder approval for the acquisition, expected in Q3 2022; Apogee's pipeline progress, particularly its Phase 3 atopic dermatitis trial results due in late 2022; and regulatory clearance from the relevant authorities, anticipated in early 2023.
Market impact: The healthcare sector, particularly biopharmaceutical companies, is affected. AbbVie, a major player, is diversifying its pipeline, potentially driving future growth. Apogee shareholders benefit from a 60% premium, while AbbVie investors may scrutinize the deal's impact on AbbVie's valuation, which currently trades at a richer multiple than Nvidia.
What to watch next: AbbVie's shareholder approval for the acquisition, expected in Q3 2022; Apogee's pipeline progress, particularly its Phase 3 atopic dermatitis trial results due in late 2022; and regulatory clearance from the relevant authorities, anticipated in early 2023.
AI Overview as of Jun 22, 2026
Timeline
Last UpdatedJun 21, 2026